Qlife Holding AB (publ) (STO:QLIFE)

Sweden flag Sweden · Delayed Price · Currency is SEK
2.020
+0.030 (1.51%)
At close: Mar 4, 2026
Market Cap31.67M +128.9%
Revenue (ttm)324.00K +548.0%
Net Income-20.56M
EPS-1.64
Shares Out15.68M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume19,083
Average Volume45,422
Open1.960
Previous Close1.990
Day's Range1.955 - 2.040
52-Week Range1.205 - 5.740
Beta0.65
RSI45.59
Earnings DateFeb 11, 2026

About Qlife Holding AB

Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents in Sweden. The company offers Egoo.Health Platform, a product platform that enables advanced biomarker testing, consisting of a small device, disposable capsules, and the supplementing software. Its biomarkers include CRP/C-reactive protein, procalcitonin, Nt-pro-BNP, lipids, HbA1c/D-vitami, and D-dimer. Qlife Holding AB (publ) was incorporated in 2019 and is based in Helsingborg, Sweden. [Read more]

Sector Healthcare
Founded 2019
Employees 4
Stock Exchange Nasdaq Stockholm
Ticker Symbol QLIFE
Full Company Profile

Financial Performance

In 2025, Qlife Holding AB's revenue was 324,000, an increase of 548.00% compared to the previous year's 50,000. Losses were -20.56 million, -63.24% less than in 2024.

Financial Statements